An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
VERDICT
The label
Markdown
read at $7.53
CorMedix Inc. holds its Markdown at $7.53.
PHPhase · the trend structure carries the Markdown label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
POSITION
Titan Case StudyActive
We put real conviction behind this one — a live position we track in the open, reported honestly whether it works or not. This is not just analysis.
Entered2026-07-01
Entry price$8.36
Entry phaseAccumulation
Now · 2026-07-31$7.53
Since entry-9.9%
ThesisAccumulation regime in FDA-approved healthcare micro-cap. Smart money loading before crowd notices. Monitor for markup transition.
A real, dated position · reported honestly whether it works or not. Analysis, not advice.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-31
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 108 days
Price
$7.53
Valuation
3.63 trailing · 22.49 forward price to earnings
Values screen
PASS· score 81.9
Beta
1.48
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads STRONG OPPORTUNITY — it trades at roughly a 51% discount to our $11.35 fair value, strong competitive moat, 226.10% revenue growth.
Read at
$7.53
3.63 P/E · 22.49 fwd
Our fair value
$11.35
51% discount
Analyst target (avg)
$15.00
+99% to current
Target low $13.00Analyst target rangeTarget high $19.00
▲ current $7.53 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$7.53
you are here
Conservative
$11.35
+51%
Analyst avg
$15.00
+99%
Our fair value
$11.35
+51%
Analyst high
$19.00
+152%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
226.10%
Profit margin
45.25%
Debt to equity
33.73
Analyst consensus
None · 5 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 23.9% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 23.9% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 0.0% of assets, under the 49% limit.Pass
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
The biotech that finally got its yes
For years CorMedix was the definition of a lottery-ticket biotech: one drug, no approval, and a share price that lived and died on FDA letters. That story is over. DefenCath — a lock solution that stops the bloodstream infections which plague dialysis patients on catheters — is approved and selling, and the numbers coming out the other side look nothing like the old CorMedix.
Why it stands out. Revenue is growing at a triple-digit clip as DefenCath rolls into dialysis clinics, the company has crossed into profitability, and it clears our ethical screen cleanly. At around $8.40 it trades below our roughly $11 fair value, and the analysts covering it see more — targets run to the mid-teens. A company with an approved, reimbursed product finding its commercial feet is a fundamentally different animal from the pre-approval gamble the market still half-remembers.
The honest risk. It is still, essentially, a one-product company. The whole thesis rides on how quickly clinics adopt DefenCath and how payers reimburse it, and a stumble on either would hurt. It's a small-cap, so the price swings harder than the market, and the usual healthcare wildcards — competition, regulation — apply. This is not a widow-and-orphans holding.
Where we land. Fair value around $11, roughly a third above today's price, with the analyst crowd more bullish still. We track it as a live case study because it's exactly the kind of name our screens are built to catch early — a real product and real cash flow arriving before the wider market re-rates the story. Risk is high, call it 65%, almost all of it execution and single-product concentration. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
CRMD trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.5% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (5 analysts) rates it buy, with a mean price target of $15. Entered 2026-07-25 · Markdown
JOURNAL
The dated journal · newest first, never edited
2026-07-25Markdown · changed$7.87-6.5%Entry 4
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.5% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (5 analysts) rates it buy, with a mean price target of $15.
2026-07-18Accumulation$8.42+0.7%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.7% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (5 analysts) rates it buy, with a mean price target of $15.
2026-07-03Accumulation$8.36+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$8.36Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
